MARKET

KZR

KZR

Kezar Life Sciences
NASDAQ
0.9030
+0.0091
+1.02%
Pre Market: 0.9101 +0.0071 +0.79% 08:47 03/28 EDT
OPEN
0.8850
PREV CLOSE
0.8939
HIGH
0.9076
LOW
0.8525
VOLUME
800
TURNOVER
0
52 WEEK HIGH
3.660
52 WEEK LOW
0.6746
MARKET CAP
65.74M
P/E (TTM)
-0.6431
1D
5D
1M
3M
1Y
5Y
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Kezar Life Sciences (KZR), Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF) and Cue Health (HLTH)
TipRanks · 3d ago
Weekly Report: what happened at KZR last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at KZR last week (0311-0315)?
Weekly Report · 03/18 09:23
Kezar Life Sciences Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Dow Jones · 03/15 10:53
HC Wainwright & Co. Reiterates Buy on Kezar Life Sciences, Maintains $20 Price Target
Benzinga · 03/15 10:43
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 03/15 10:30
KZR Stock Earnings: Kezar Life Sciences Misses EPS for Q4 2023
Kezar Life Sciences reported earnings per share of -44 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -38 cents. Kezar Life Sciences is a subsidiary of Kezar Pharmaceuticals.
Investorplace · 03/15 01:54
Kezar Life Sciences GAAP EPS of -$0.44
Seeking Alpha · 03/14 21:50
More
About KZR
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.

Webull offers Kezar Life Sciences Inc stock information, including NASDAQ: KZR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KZR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KZR stock methods without spending real money on the virtual paper trading platform.